secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT)
CIK:        0000315545
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001493152-23-022116
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Provectus Biopharma stockholders authorize reverse stock split and reduce authorized shares
--------------------------------------------------------------------------------

- Reverse stock split approved (321.7M for) at ratio of 1:10 to 1:50, Board to determine exact ratio.
- Authorized share reduction approved (325.4M for) decreasing authorized shares by same reverse split ratio.
- Directors elected: Bailey, Horowitz, Lacey, Pershing, Rodrigues – each with over 227M votes for.
- Ratification of Marcum LLP as independent auditor for 2023 passed with 354.4M votes for.
- Advisory vote on executive compensation approved (226.1M for); board will hold annual say-on-pay vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/315545/000149315223022116/0001493152-23-022116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/315545/000149315223022116/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-022116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer